Cardiac stem cell and myocyte secreted paracrine factors

A method for screening a cardiac patient as a candidate for stem cell therapy, said method comprising measuring in a biological sample from the patient the amount of apolipoprotein E precursor, atriopeptigen (ANP, ANF), adrenomedullin, brain acid soluble protein 1 (BASP 1 protein), cathepsin B precursor, collagen alpha-1 (VI) chain precursor, connective tissue growth factor, cystatin E/M, Dkk3 protein, insulin-like growth factor-binding protein 2 precursor, interleukin-1 receptor-like 1 precursor (ST2), matrix metallopeptidase 2, metalloproteinase inhibitor 1 precursor (TIMP-1), metalloproteinase inhibitor 2 precursor (TIMP-2), mimecan precursor, procollagen type III alpha 1, procollagen type V alpha 1 and tropoelastin, comparing said measurement to a baseline value, wherein a statistically significant amount of the protein(s) compared to the baseline value indicates that the patient would be likely to benefit from stem cell therapy.